Effective August 2, 2022, mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Additionally, Genomic Health Inc, part of Exact Sciences, will continue to perform the GPS test during the transition. Further communications explaining transition plans will be provided in the coming months. For more details, please review the press release.
Questions? Email: gps@mdxhealth.com
Region: United States

origin: oncology genomic testing

A portfolio of Exact genomic solutions that delivers actionable insights on treatment determination and therapy selection to inform personalized decisions.

We're defining a new approach to oncology genomics.
Experience Exactionable

Exact Sciences’ Precision Oncology Portfolio of Tests

Treatment Determination

The Oncotype DX® tests deliver clinically relevant genomic intelligence specific to the individual biology of a patient’s tumor—equipping physicians with the Exact insights they need.

Therapy Selection

The Oncomap™ tests deliver rapid and comprehensive tumor profiling that aids therapy selection for patients with advanced or metastatic cancer—utilizing a complete biological picture to match their needs.

Raise your Exactations

with genomic information for each patient’s situation.

News & Events

News August 02, 2022

Update on the Genomic Prostate Score test

mdxhealth has acquired the Oncotype DX Genomic Prostate Score (GPS) test from Exact Sciences. Exact Sciences will continue to perform the GPS test during the transition.
Conference June 04, 2022

2022 ASCO Annual Meeting

Join us in Chicago, IL for the 2022 ASCO Annual Meeting to learn more about the updated ASCO Guidelines.
News April 28, 2022

ASCO Guidelines

Updated ASCO Guidelines strongly recommend use of the Oncotype DX Breast Recurrence Score® Test in node-negative and the majority of node-positive early-stage breast cancer patients

FOR PATIENTS

Genomic testing can help inform the right cancer treatment decision for you

It's important to know everything you can about genomic tests; that way, you and your doctor can make an informed decision together.

Learn more about genomic testing

Real patients share their stories of inspiration

  • Deepa's Story

    A surgeon diagnosed with node negative, invasive breast cancer who used the Oncotype DX Breast Recurrence Score test to help inform a decision to not get chemotherapy...

  • Amy’s Story

    A radiology technician diagnosed with ductal carcinoma in situ (DCIS) who used the Oncotype DX Breast DCIS Score test to help her learn that her likelihood of tumor recurrence was very low...

  • Lloyd’s Story

    A financial executive diagnosed with early-stage prostate cancer who used his Oncotype DX Genomic Prostate Score result to choose active surveillance over invasive treatment...

    • Billing & Coverage

    Exact Sciences believes that everyone should have access to the information they need to make informed decisions about their cancer treatment. That’s why we offer the Genomic Access Program (GAP) to help patients navigate the insurance and billing process.

    Explore Billing & Coverage options

    We’ve set the Exactations high

    Over 1 million patients benefited from Oncotype DX® tests

    Helping them avoid over/undertreatment in breast, prostate, and colon cancers.

    Have questions?

    +1 866-662-6897

    Email Customer Service

    Contact Us